Breaking the big Five Barriers of Brain Metastasis: A prospective phase II, open-label, multi-center trial of combined nivolumab, ipilimumab and bevacizumab together with 2 cycles of induction chemotherapy in patients with non-squamous non-small-cell lung cancer (NSCLC) metastatic to the brain (Break B5-BM NSCLC Trial)

Nivolumab (Opdivo®), Ipilimumab (Yervoy®), Bevacizumab (Zirabev®)

Status: In Rekrutierung

Klinische Settings

Beteiligte

Identifier

Links

Kontakt